Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT00247455 Completed - Obesity Clinical Trials

Fibre and Appetite Regulation Trial (FART)

Start date: March 2002
Phase: N/A
Study type: Interventional

High intake of cereal fibre has been shown to be associated with reduced weight gain and improved insulin sensitivity. We hypothesize these effects are due to the short chain fatty acids derived from the bacterial fermentation (breakdown) of fibre in the colon (large intestine). Insulin resistant subjects will be randomized to receive 2 servings of a low-fibre cereal (eg. puffed rice) or 2 servings of a high-fibre cereal (wheat bran cereal) per day for one year. The effects of the diets on body weight, appetite, abdominal fat, blood short chain fatty acids, glucose, insulin, lipids and hormones will be measured

NCT ID: NCT00246987 Completed - Diabetes, Type 2 Clinical Trials

A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

Start date: June 2003
Phase: Phase 3
Study type: Interventional

To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.

NCT ID: NCT00246623 Completed - Clinical trials for Diabetes Mellitus, Type 2

US Inhaled Insulin Dose Titration Study

Start date: November 2005
Phase: Phase 3
Study type: Interventional

This study will examine how to dose Exubera (inhaled insulin) in patients who are not well controlled on two or more diabetes pills. This study should show that a large number of patients enrolled in the study can reach the target Hemoglobin A1C levels (7% or less) that have been set by the American Diabetes Association (ADA). Target goals should be achieved by adjusting the Exubera dose either weekly or twice weekly. Patients will also receive nutritional counseling and diabetes education as part of the study.

NCT ID: NCT00245882 Completed - Diabetes Clinical Trials

The Diabetes Telemonitoring (DiaTel) Study

DiaTel
Start date: October 2005
Phase: N/A
Study type: Interventional

The purpose of this research study is to compare two different methods of helping veterans with diabetes better manage their disease. This study will compare an "Active Care Management" method using home-based technology and self-monitoring techniques with a lower-intensity "Care Coordination" method based on monthly telephone contact with a nurse.

NCT ID: NCT00241904 Completed - Hypertension Clinical Trials

Reducing Total Cardiovascular Risk in an Urban Community

COACH
Start date: May 2006
Phase: N/A
Study type: Interventional

PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER. The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular risk reduction programs - a comprehensive intensive (Cl) intervention with a less intensive (LI) intervention - in African American, and white low-income patients with known excessive cardiovascular disease risk.

NCT ID: NCT00241605 Completed - Clinical trials for Diabetes Mellitus, Type 2

AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus

Start date: June 25, 2003
Phase: Phase 4
Study type: Interventional

This 48-week study will compare AVANDAMET vs. Metformin monotherapy for blood glucose control in patients with Type 2 Diabetes Mellitus.

NCT ID: NCT00240422 Completed - Hypertension Clinical Trials

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

Start date: February 2003
Phase: Phase 4
Study type: Interventional

The primary objective is to evaluate the effect of 9 weeks treatment with either telmisartan or ramipril on NO bioavailability in the renal vasculature, measured as renal plasma flow (RPF) in response to NG-monomethyl-L-arginine (LNMMA) infusion.

NCT ID: NCT00240383 Completed - Clinical trials for Diabetes Mellitus II

Dose Ranging Study With LT, Monotherapy, PPAR

Start date: May 2002
Phase: Phase 2/Phase 3
Study type: Interventional

A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

NCT ID: NCT00240175 Completed - Diabetes Clinical Trials

Evaluating the Effects of Foot Orthotics on Plantar Pressures in the Diabetic Population

Start date: August 2005
Phase: Phase 1
Study type: Interventional

Foot orthotics or shoe inserts are currently utilized as a common conservative treatment option for a wide variety of foot disorders. This treatment is used for both the relatively healthy active population and the more sedentary population with diabetes or peripheral vascular disease (dysvascular). However, there is limited objective scientific data documenting the actual benefits or effectiveness of either customized or over-the-counter foot orthoses. It is the aim of this study to determine the effects of three popular foot orthotics on plantar pressures in diabetic populations. If foot orthoses can be utilized as a preventive treatment option to reduce the risk for foot ulceration by redistributing plantar pressures, then orthoses would be a cost effective solution to a high cost (mental and fiscal) medical impairment.

NCT ID: NCT00239538 Completed - Hypertension Clinical Trials

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Start date: January 2003
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to demonstrate that telmisartan 80 mg combined with hydrochlorothiazide 12.5 mg (T80/H12.5) is at least as effective and possibly superior to valsartan 160 mg combined with hydrochlorothiazide 12.5 mg (V160/H12.5) in lowering mean ambulatory systolic blood pressure (SBP) and diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing interval at the end of a 10-week treatment period in mild-to-moderate hypertensive, overweight or obese patients with type 2 diabetes mellitus